← Back to Search

P2Y12 Inhibitor

Cangrelor for Acute Coronary Syndrome (Platform Trial)

Phase 3
Waitlist Available
Led By Deepak L. Bhatt, MD
Research Sponsored by The Medicines Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Angiography demonstrating atherosclerosis amenable to treatment by percutaneous coronary intervention (PCI) with or without stent implantation and diagnosis of Acute Coronary Syndrome (ACS) by elevated cardiac markers or ischemic chest discomfort w/electrocardiogram changes + age \> 65 or diabetes.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up randomization through 48 hours post randomization
Awards & highlights

Summary

The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality, myocardial infarction (MI), and ischemia-driven revascularization (IDR).

Eligible Conditions
  • Acute Coronary Syndrome
  • Atherosclerosis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during index pci
This trial's timeline: 3 weeks for screening, Varies for treatment, and during index pci for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)
Secondary outcome measures
Incidence of ACUITY Major Bleeding
Incidence of ACUITY Major Bleeding Without Hematoma >/= 5 cm
Incidence of All-cause Mortality
+9 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: CangrelorExperimental Treatment3 Interventions
cangrelor bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion
Group II: ClopidogrelActive Control3 Interventions
placebo bolus \& infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cangrelor
FDA approved
Clopidogrel
FDA approved

Find a Location

Who is running the clinical trial?

The Medicines CompanyLead Sponsor
71 Previous Clinical Trials
72,291 Total Patients Enrolled
8 Trials studying Acute Coronary Syndrome
37,306 Patients Enrolled for Acute Coronary Syndrome
Simona Skerjanec, PharmDStudy DirectorThe Medicines Company
1 Previous Clinical Trials
8,882 Total Patients Enrolled
1 Trials studying Acute Coronary Syndrome
8,882 Patients Enrolled for Acute Coronary Syndrome
Deepak L. Bhatt, MDPrincipal InvestigatorThe Cleveland Clinic
4 Previous Clinical Trials
48,745 Total Patients Enrolled
1 Trials studying Acute Coronary Syndrome
8,882 Patients Enrolled for Acute Coronary Syndrome
~282 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top